SMI: Diabetes

1 October 2013 to 2 October 2013
London, United Kingdom

Linking business with information.

Benefits of attending:

  • From concept to clinical practice: identify novel therapeutic targets
  • Keep well informed with new EU and FDA guidelines on clinical trials and risk-benefit assessment
  • Identify successes in clinical development and efficacy studies
  • Receive clinical updates on novel receptor agonists e.g. SLGT2 and DPP-4 inhibitors
  • Discuss future medicine and the role of synthetic biology
  • Discover methods to reduce costs in large scale outcome trials
  • Validate target engagement biomarkers
  • Build relationships with key industry and academic professionals

Conference website